Exubera inhaled insulin: Long-term study; Phase III

In a Phase III trial in 145 patients, significantly more patients receiving Exubera achieved the primary endpoint of HbA1c levels of 8%

Read the full 224 word article

How to gain access

Continue reading with a
two-week free trial.